Blonanserin

Abstract

Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials. Notably, in two randomized, double-blind trials of 8 weeks' duration, blonanserin was noninferior to haloperidol or risperidone for primary endpoints, although it appeared to be better than haloperidol in improving negative symptoms. Blonanserin is generally well tolerated and appears to have an acceptable profile in terms of bodyweight gain. Potential tolerability benefits of the drug in short-term trials included fewer extrapyramidal symptoms than haloperidol and fewer reports of prolactin level increases or hyperprolactinaemia than risperidone. Nevertheless, extrapyramidal symptoms and hyperprolactinaemia were among the most common adverse reactions associated with blonanserin in noncomparative long-term studies. Further prospective and long-term comparative studies are required in order to definitively position blonanserin with respect to other antipsychotic agents. In the meantime, available clinical data suggest that blonanserin is an effective and generally well tolerated option for the short-term treatment of schizophrenia and for those requiring longer-term therapy.

Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database

“…22) The incidence of EPS due to Blonanserin is lower than that due to Haloperidol. 23) Similar to a previous study, 21) from the analysis of safety signal in this study, Risperidone showed the expression risk on an equal footing with Haloperidol. However, this study was diŠerent from Hosomi et al report 24) about Paliperidone, Perospirone, and Blonanserin.…”

Sensitive Analysis of Blonanserin, a Novel Antipsychotic Agent, in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry

“…[1][2][3][4][5][6] It is one of the secondgeneration antipsychotic agents, together with risperidone and olanzapine, it is effective in the treatment of both positive and negative symptoms of schizophrenia without extra-pyramidal symptoms, but has original properties of affinity higher for the dopamine D2 receptor than for the serotonin 5-HT2A receptor. [1][2][3][4]6,7 On the other hand, blonanserin is much less potent in adrenergic-α1, histamine H1 and muscarinic M1 antagonist activities. 6 Such a pharmacological profile shows that blonanserin is more specific to the dopamine D2 and serotonin 5-HT2A receptors with fewer side effects; its excellent effects on schizophrenia have been reported in many reports.…”

“…6 Such a pharmacological profile shows that blonanserin is more specific to the dopamine D2 and serotonin 5-HT2A receptors with fewer side effects; its excellent effects on schizophrenia have been reported in many reports. [7][8][9][10] There is a possibility that this drug will gain popularity for treatment of schizophrenia throughout the world.…”

Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study

“…1(A)), first developed by Dainippon Sumitomo Pharma Company in Japan in 2008, is a novel atypical antipsychotic that is validated for the treatment of both positive and negative symptoms of schizophrenia, without extra-pyramidal symptoms [1][2][3][4][5][6]. It has a high affinity with dopamine D 2 and 5-HT 2A , while being much less potent in adrenergic-␣ 1 , histamine H 1 , and muscarinic M 1 antagonist activities [4].…”

“…Pharmacokinetic data for blonanserin are limited and available from the manufacturer's prescribing information [8] or unpublished sources [9] presented by Deeks [2]. Blonanserin is rapidly absorbed orally and extensively metabolized.…”